Analyst Price Targets — KYMR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 31, 2026 11:09 am | Brad Canino | Guggenheim | $170.00 | $118.15 | StreetInsider | Kymera Therapeutics (KYMR) PT Raised to $170 at Guggenheim |
| August 6, 2026 4:13 pm | Judah Frommer | Morgan Stanley | $135.00 | $104.96 | TheFly | Kymera Therapeutics price target raised to $135 from $119 at Morgan Stanley |
| August 6, 2026 9:34 am | — | Barclays | $139.00 | $105.48 | TheFly | Kymera Therapeutics price target raised to $139 from $133 at Barclays |
| August 5, 2026 6:56 pm | Jeff Jones | Oppenheimer | $125.00 | $105.48 | StreetInsider | Kymera Therapeutics (KYMR) PT Raised to $125 at Oppenheimer |
| July 30, 2026 6:12 am | David Hoang | Deutsche Bank | $120.00 | $105.25 | StreetInsider | Deutsche Bank Starts Kymera Therapeutics (KYMR) at Hold |
| July 28, 2026 10:38 am | — | Guggenheim | $135.00 | $110.05 | TheFly | Kymera Therapeutics price target raised to $135 from $125 at Guggenheim |
| July 16, 2026 10:48 am | Joseph Catanzaro | Mizuho Securities | $140.00 | $114.12 | TheFly | Kymera Therapeutics price target raised to $140 from $120 at Mizuho |
| July 13, 2026 10:34 am | Brian Abrahams | RBC Capital | $115.00 | $119.35 | TheFly | Kymera Therapeutics downgraded to Sector Perform from Outperform at RBC Capital |
| June 29, 2026 11:22 am | Srikripa Devarakonda | Truist Financial | $136.00 | $108.12 | TheFly | Kymera Therapeutics price target raised to $136 from $116 at Truist |
| June 26, 2026 11:55 am | Edward Nash | Canaccord Genuity | $129.00 | $116.46 | TheFly | Kymera Therapeutics price target raised to $129 from $106 at Canaccord |
Latest News for KYMR
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 21st Annual Healthcare Conference in Boston, MA…
Enrollment completed in KT-621 BROADEN2 Phase 2b AD trial with topline data expected by year-end 2026; Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected in late 2027 WATERTOWN, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small…
Bank of New York Mellon Corp purchased a new position in shares of Kymera Therapeutics, Inc. (NASDAQ: KYMR) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 215,588 shares of the company's stock, valued at approximately $24,721,000. Bank of New York
Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KYMR.
U.S. House Trading
No House trades found for KYMR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.